The United States on Friday approved the first blood test for Alzheimer's, a move that could help patients begin treatment ...

The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among ...

The US on Friday approved the first blood test for Alzheimer's, a move that can help patients begin treatment earlier with ...

Donanemab – one of the first drugs to slow down early-stage Alzheimer’s disease – will not be available on the NHS in ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

This groundbreaking research reveals that subtle chemical changes in tau may quietly set off a chain reaction, spreading ...

Four South Florida sites are enrolling people with memory loss into a national trial for benfotiamine, a lab-made vitamin ...

"This report may help patients and providers better understand the risks of treatment, which are lower in patients with very mild symptoms of Alzheimer's." Lecanemab and donanemab (Kisunla ...

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques.

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

LEXINGTON For the past four decades, the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) has been at the ...